These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 15667139)

  • 61. Structural requirements of pyrido[2,3-d]pyrimidin-7-one as CDK4/D inhibitors: 2D autocorrelation, CoMFA and CoMSIA analyses.
    Caballero J; Fernández M; González-Nilo FD
    Bioorg Med Chem; 2008 Jun; 16(11):6103-15. PubMed ID: 18468903
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Modeling ligand-receptor interaction for some MHC class II HLA-DR4 peptide mimetic inhibitors using several molecular docking and 3D QSAR techniques.
    Wei HY; Tsai KC; Lin TH
    J Chem Inf Model; 2005; 45(5):1343-51. PubMed ID: 16180911
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) of anthranilamide derivatives that are multidrug resistance modulators.
    Labrie P; Maddaford SP; Fortin S; Rakhit S; Kotra LP; Gaudreault RC
    J Med Chem; 2006 Dec; 49(26):7646-60. PubMed ID: 17181148
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Molecular modeling studies of N-substituted pyrrole derivatives--potential HIV-1 gp41 inhibitors.
    Teixeira C; Barbault F; Rebehmed J; Liu K; Xie L; Lu H; Jiang S; Fan B; Maurel F
    Bioorg Med Chem; 2008 Mar; 16(6):3039-48. PubMed ID: 18226912
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Inhibitory mode of N-phenyl-4-pyrazolo[1,5-b] pyridazin-3-ylpyrimidin-2-amine series derivatives against GSK-3: molecular docking and 3D-QSAR analyses.
    Xiao J; Guo Z; Guo Y; Chu F; Sun P
    Protein Eng Des Sel; 2006 Feb; 19(2):47-54. PubMed ID: 16339768
    [TBL] [Abstract][Full Text] [Related]  

  • 66. 3D-QSAR CoMFA/CoMSIA studies on 5-aryl-2,2-dialkyl-4-phenyl-3(2H)-furanone derivatives, as selective COX-2 inhibitors.
    Puntambekar DS; Giridhar R; Yadav MR
    Acta Pharm; 2006 Jun; 56(2):157-74. PubMed ID: 16613723
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Essential structural profile of a dual functional inhibitor against cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX): molecular docking and 3D-QSAR analyses on DHDMBF analogues.
    Zheng M; Zhang Z; Zhu W; Liu H; Luo X; Chen K; Jiang H
    Bioorg Med Chem; 2006 May; 14(10):3428-37. PubMed ID: 16458008
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Comparative molecular field analysis of flavonoid inhibitors of the PIM-1 kinase.
    Holder S; Lilly M; Brown ML
    Bioorg Med Chem; 2007 Oct; 15(19):6463-73. PubMed ID: 17637507
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Modeling aided design of potent glycogen phosphorylase inhibitors.
    Deng Q; Lu Z; Bohn J; Ellsworth KP; Myers RW; Geissler WM; Harris G; Willoughby CA; Chapman K; McKeever B; Mosley R
    J Mol Graph Model; 2005 Apr; 23(5):457-64. PubMed ID: 15781188
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Acyl ureas as human liver glycogen phosphorylase inhibitors for the treatment of type 2 diabetes.
    Klabunde T; Wendt KU; Kadereit D; Brachvogel V; Burger HJ; Herling AW; Oikonomakos NG; Kosmopoulou MN; Schmoll D; Sarubbi E; von Roedern E; Schönafinger K; Defossa E
    J Med Chem; 2005 Oct; 48(20):6178-93. PubMed ID: 16190745
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Receptor- and ligand-based 3D-QSAR study for a series of non-nucleoside HIV-1 reverse transcriptase inhibitors.
    Hu R; Barbault F; Delamar M; Zhang R
    Bioorg Med Chem; 2009 Mar; 17(6):2400-9. PubMed ID: 19250835
    [TBL] [Abstract][Full Text] [Related]  

  • 72. 3D-QSAR studies of arylpyrazole antagonists of cannabinoid receptor subtypes CB1 and CB2. A combined NMR and CoMFA approach.
    Chen JZ; Han XW; Liu Q; Makriyannis A; Wang J; Xie XQ
    J Med Chem; 2006 Jan; 49(2):625-36. PubMed ID: 16420048
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Thermodynamic characterization of allosteric glycogen phosphorylase inhibitors.
    Anderka O; Loenze P; Klabunde T; Dreyer MK; Defossa E; Wendt KU; Schmoll D
    Biochemistry; 2008 Apr; 47(16):4683-91. PubMed ID: 18373353
    [TBL] [Abstract][Full Text] [Related]  

  • 74. 3D QSAR CoMFA/CoMSIA, molecular docking and molecular dynamics studies of fullerene-based HIV-1 PR inhibitors.
    Durdagi S; Mavromoustakos T; Papadopoulos MG
    Bioorg Med Chem Lett; 2008 Dec; 18(23):6283-9. PubMed ID: 18951793
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Molecular docking and 3D-QSAR studies of 2-substituted 1-indanone derivatives as acetylcholinesterase inhibitors.
    Shen LL; Liu GX; Tang Y
    Acta Pharmacol Sin; 2007 Dec; 28(12):2053-63. PubMed ID: 18031622
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Endogenous effectors of human liver glycogen phosphorylase modulate effects of indole-site inhibitors.
    Ercan-Fang N; Taylor MR; Treadway JL; Levy CB; Genereux PE; Gibbs EM; Rath VL; Kwon Y; Gannon MC; Nuttall FQ
    Am J Physiol Endocrinol Metab; 2005 Sep; 289(3):E366-72. PubMed ID: 15797986
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Application of 3D QSAR CoMFA/CoMSIA and in silico docking studies on novel renin inhibitors against cardiovascular diseases.
    Politi A; Durdagi S; Moutevelis-Minakakis P; Kokotos G; Papadopoulos MG; Mavromoustakos T
    Eur J Med Chem; 2009 Sep; 44(9):3703-11. PubMed ID: 19410337
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Discovering benzamide derivatives as glycogen phosphorylase inhibitors and their binding site at the enzyme.
    Chen L; Li H; Liu J; Zhang L; Liu H; Jiang H
    Bioorg Med Chem; 2007 Nov; 15(21):6763-74. PubMed ID: 17719791
    [TBL] [Abstract][Full Text] [Related]  

  • 79. 3D-QSAR and molecular docking studies of benzaldehyde thiosemicarbazone, benzaldehyde, benzoic acid, and their derivatives as phenoloxidase inhibitors.
    Xue CB; Zhang L; Luo WC; Xie XY; Jiang L; Xiao T
    Bioorg Med Chem; 2007 Mar; 15(5):2006-15. PubMed ID: 17258462
    [TBL] [Abstract][Full Text] [Related]  

  • 80. 3D-QSAR studies of boron-containing dipeptides as proteasome inhibitors with CoMFA and CoMSIA methods.
    Zhu YQ; Lei M; Lu AJ; Zhao X; Yin XJ; Gao QZ
    Eur J Med Chem; 2009 Apr; 44(4):1486-99. PubMed ID: 18771818
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.